Home » Stocks » MBRX

Moleculin Biotech, Inc. (MBRX)

Stock Price: $3.44 USD -0.19 (-5.23%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $3.45 +0.01 (0.29%) Apr 16, 7:58 PM
Market Cap 103.25M
Revenue (ttm) n/a
Net Income (ttm) -17.36M
Shares Out 9.85M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $3.44
Previous Close $3.63
Change ($) -0.19
Change (%) -5.23%
Day's Open 3.60
Day's Range 3.37 - 3.58
Day's Volume 987,633
52-Week Range 3.16 - 55.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HOUSTON, April 14, 2021 /PRNewswire/ --  Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target...

3 days ago - PRNewsWire

HOUSTON, April 6, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

1 week ago - PRNewsWire

The FDA has approved Moleculin Biotech Inc's (NASDAQ: MBRX) request for Fast Track Designation for its drug, Annamycin, to treat soft tissue sarcoma (STS) lung metastases. The designation marks the seco...

2 weeks ago - Benzinga

HOUSTON, March 30, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi...

2 weeks ago - PRNewsWire

HOUSTON, March 24, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi...

3 weeks ago - PRNewsWire

HOUSTON, March 9, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

1 month ago - PRNewsWire

HOUSTON, Feb. 10, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

2 months ago - PRNewsWire

HOUSTON, Feb. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting high...

2 months ago - PRNewsWire

HOUSTON, Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting ...

2 months ago - PRNewsWire

HOUSTON, Feb. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting high...

2 months ago - PRNewsWire

HOUSTON, Jan. 29, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

2 months ago - PRNewsWire

Moleculin Biotech (MBRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

HOUSTON, Jan. 7, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting high...

3 months ago - PRNewsWire

HOUSTON, Dec. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

3 months ago - PRNewsWire

HOUSTON, Dec. 17, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

4 months ago - PRNewsWire

HOUSTON, Dec. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting high...

4 months ago - PRNewsWire

Moleculin Biotech (MBRX) is seeing shares of MBRX stock soar higher on Tuesday after announcing news concerning one of its drug candidates. The post MBRX Stock: Why Moleculin Biotech Is Soaring 21% Toda...

4 months ago - InvestorPlace

HOUSTON, Dec. 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting high...

4 months ago - PRNewsWire

HOUSTON, Nov. 19, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

4 months ago - PRNewsWire

HOUSTON, Nov. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

5 months ago - PRNewsWire

HOUSTON, Oct. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

5 months ago - PRNewsWire

HOUSTON, Oct. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting sig...

5 months ago - PRNewsWire

HOUSTON, Oct. 21, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting sig...

5 months ago - PRNewsWire

HOUSTON, Oct. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting sig...

6 months ago - PRNewsWire

HOUSTON, Oct. 6, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting sign...

6 months ago - PRNewsWire

HOUSTON, Oct. 5. 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting sign...

6 months ago - PRNewsWire

HOUSTON, Oct. 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting sign...

6 months ago - PRNewsWire

HOUSTON, Sept. 14, 2020 /PRNewswire/ -- Moleculin Biotech, Inc.

7 months ago - PRNewsWire

HOUSTON, Sept. 10, 2020 /PRNewswire/ -- Moleculin Biotech, Inc.

7 months ago - PRNewsWire

HOUSTON, Sept. 9, 2020 /PRNewswire/ -- Moleculin Biotech, Inc.

7 months ago - PRNewsWire

HOUSTON, Aug. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc.

7 months ago - PRNewsWire

HOUSTON, Aug. 12, 2020 /PRNewswire/ -- Moleculin Biotech, Inc.

8 months ago - PRNewsWire

HOUSTON, July 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

8 months ago - PRNewsWire

Moleculin Biotech Inc. (NASDAQ: MBRX) joins the ever-expanding list of coronavirus stocks as the company announced that a second round of independent laboratory testing has confirmed the antiviral activ...

8 months ago - 24/7 Wall Street

Shares of small-cap Moleculin Biotech Inc. soared 43% in premarket trade Tuesday, after the company said a second round of laboratory testing confirmed antiviral activity for WP1122, its candidate as a ...

8 months ago - Market Watch

HOUSTON, July 21, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

8 months ago - PRNewsWire

Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.

9 months ago - Zacks Investment Research

HOUSTON, July 15, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

9 months ago - PRNewsWire

Is (MBRX) Outperforming Other Medical Stocks This Year?

9 months ago - Zacks Investment Research

HOUSTON, July 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting ...

9 months ago - PRNewsWire

In the latest trading session, Moleculin Biotech, Inc. (MBRX) closed at $0.96, marking a -0.38% move from the previous day.

9 months ago - Zacks Investment Research

HOUSTON, July 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting ...

9 months ago - PRNewsWire

HOUSTON, June 25, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

9 months ago - PRNewsWire

HOUSTON, June 23, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

9 months ago - PRNewsWire

Is (MBRX) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

HOUSTON, June 16, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today an...

10 months ago - PRNewsWire

HOUSTON, June 4, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today ann...

10 months ago - PRNewsWire

HOUSTON, June 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today ann...

10 months ago - PRNewsWire

HOUSTON, May 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting ...

10 months ago - PRNewsWire

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that the trading halt status in Moleculin Biotech Inc. (Nasdaq: MBRX) was changed to "additional informatio...

10 months ago - GlobeNewsWire

About MBRX

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as... [Read more...]

Industry
Biotechnology
IPO Date
Jun 2, 2016
Stock Exchange
NASDAQ
Ticker Symbol
MBRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for MBRX stock is "Buy." The 12-month stock price forecast is 20.33, which is an increase of 490.99% from the latest price.

Price Target
$20.33
(490.99% upside)
Analyst Consensus: Buy